Pelican Bay Capital Initiates Zoetis Stake Citing 8% Organic Growth, $50 B Pet Market
Pelican Bay Capital’s Concentrated Value Strategy returned 8.5% in Q4 2025 versus a 3.8% Russell 1000 Value Index gain and for the full year delivered 20.6% against 15.9%, driven in part by a new position in Zoetis. Zoetis, with a $56.2 billion market cap, has achieved 8% organic annual revenue growth since its 2013 spin-out and is targeting five blockbuster drug approvals over the next five years in a $50 billion animal health market growing 5–6% annually.
1. Fund Performance and Zoetis Inclusion
Pelican Bay Capital Management’s Concentrated Value Strategy outperformed in Q4 2025, returning 8.5% versus a 3.8% Russell 1000 Value Index gain and 20.6% for the full year against 15.9%. In its Q4 investor letter, the firm highlighted Zoetis as a new addition to its top five holdings, underscoring a focus on high-quality companies with robust balance sheets.
2. Zoetis Market Position and Growth
Zoetis is the leading pharmaceutical and vaccine developer in the animal health sector, which generated approximately $50 billion last year and is forecast to grow 5–6% annually over the next decade. Since spinning out from Pfizer in 2013, Zoetis has achieved an 8% annual organic revenue growth rate, outpacing the 5% industry average, supported by rising pet ownership and increased acceptance of veterinary medicines.
3. Product Pipeline and Future Outlook
The company maintains a deep pipeline with 12 potential blockbuster products and plans to launch at least one major new drug per year over the next four years. These approvals are expected to sustain above-industry growth levels and drive share performance after a 26% share price decline over the past twelve months.